alvimopan
Phase 3- Indications
- Post-operative ileus, Opioid bowel dysfunction
Company intelligence / Profile preview
Adolor Corporation
Exton, Pennsylvania, United Statesdrugs.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 3
01
Overview
Adolor’s lead product was ENTEREG® (alvimopan), an FDA-approved mu-opioid receptor antagonist for accelerating gastrointestinal recovery post-bowel resection. The company also developed ADL5945/OpRA III for OIC/OBD in Phase 2 trials. Additional pipeline included delta opioid receptor agonists with Pfizer for chronic pain.
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small molecules (opioid receptor antagonists and agonists)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
GlaxoSmithKline (co-promotion/commercialization partner for ENTEREG until mid–2011)Pfizer Inc. (collaboration on delta opioid agonists)Eli Lilly & Co. (licensor of OpRA III/ADL5945)
Beyond the preview
Go deeper on Adolor Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adolor Corporation.